Research Practice

Clinical Study of Mesenchymal Stem/Stromal Cell Therapy for the Treatment of Frailty: A Proposed Experimental Design for Therapeutic and Mechanistic Investigation

Duc M. Hoang, PhD,1,∗ Kien T. Nguyen, MSc,1 Van T. Hoang, PhD,1 Lan T. M. Dao, PhD,1 Hang T. Bui, MD,2 Thanh T. K. Ho, MD, PhD,3 Thuy T. P. Nguyen, MD,4 Anh T. L. Ngo, BSc,5 Hoa K. Nguyen, MD, PhD,6 and Liem Nguyen Thanh, MD, PhD1,*

1Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam. 2Center of Regenerative Medicine and Cell Therapy, Vinmec Times City International Hospital, Hanoi, Vietnam. 3Hanoi Medical University, Hanoi, Vietnam. 4Dong Da General Hospital, Hanoi, Vietnam. 5Cell Therapy Department, Vinmec High-tech Center, Vinmec Healthcare System, Hanoi, Vietnam. 6Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.

∗Address correspondence to: Liem Nguyen Thanh, MD, PhD, Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Health Care System, Hanoi 100000, Vietnam. E-mail: v.liemnt@vinmec.com

Received: June 11, 2021; Editorial Decision Date: September 30, 2021

Decision Editor: David Le Couteur, MBBS, FRACP, PhD

Abstract

Frailty, a specific condition of increased vulnerability and reduced general health associated with aging in older people, is an emerging problem worldwide with major implications for clinical practice and public health. Recent preclinical and clinical studies have supported the safety of mesenchymal stem/stromal cells (MSCs) in the treatment of frailty. Comprehensive study is needed to assess the interrelationship between the condition of frailty and the effects of MSC-based therapy. This randomized controlled phase I/II trial aims to investigate the safety and potential therapeutic efficacy of the allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) in combination with the standard treatment for frailty in Vietnam. Moreover, this study describes the rationales, study designs, methodologies, and analytical strategies currently employed in stem cell research and clinical studies. The primary outcome measures will include the incidences of prespecified administration-associated adverse events and serious adverse events. The potential efficacy will be evaluated based on improvements in frailty conditions (including those determined through a physical examination, patient-reported outcomes, quality of life, immune markers of frailty, metabolism analysis, and cytokine markers from patient plasma). This clinical trial and stem cell analysis associated with patient sampling at different time points aim to identify and characterize the potential effects of UC-MSCs on improving frailty based on the stem cell quality, cytokine/growth factor secretion profiles of UC-MSCs, cellular senescence, and metabolic analysis of patient CD3+ cells providing fundamental knowledge for designing and implementing research strategies in future studies.

Clinical Trials Registration Number: NCT04919135

Keywords: Allogeneic cell therapy, Clinical trial, Stem cell phenotype, Umbilical cord

Frailty as a New Frontier of Medicine

Frailty, a specific condition of increased vulnerability and reduced general health associated with aging in older people, is an emerging problem worldwide with major implications for clinical practice and public health (1). In countries with aging populations, including Vietnam, the prevalence of frailty is increasing rapidly (2). The estimated prevalence greatly varies between countries and ranges from 4% to 59% due to the lack of a nonstandardized definition or evaluation of frailty (3). In Vietnam, a study of 461 patients at the National Geriatric Hospital in Hanoi indicated that the prevalence of frailty according to the Reported Edmonton Frail Scale was 31.9% (4). In 2001, a widely accepted clinical
description of the disease was proposed by Fried and colleagues, and this description includes 5 major criteria: (i) unintentional weight loss, (ii) weak grip strength, (iii) low gait speed, (iv) low physical activities, and (v) exhaustion (5). Based on these criteria, a patient who exhibits 1–2 symptoms is classified as prefrail, whereas a patient who presents at least 3 symptoms is diagnosed with frailty (Figure 1).

Rationale for Study Inception

Frailty is strongly associated with oxidative stress and inflammation during the aging process, which includes the following major hallmarks: (i) instability of genomic materials, (ii) reduction of telomerase activities and telomere attrition, (iii) loss of proteostasis, (iv) reduction of nutrient sensing, (v) metabolic malfunctions (including mitochondrial dysfunction), (vi) cellular senescence, (vii) stem cell depletion, and (viii) alternation of cell-to-cell communication (Figure 1) (6). These aging hallmarks play a significant role in the development of other geriatric syndromes once frailty is established and progresses in its natural courses, which include cardiovascular disease, hypertension, arthritis, and diabetes (7). Moreover, these aging-related features of frailty also alter endogenous stem cell regeneration and function, which in turn reduces the regenerative capacity of multiple organs and tissues. Toward this end, providing an exogenous stem cell population to replenish the stem cell pools and improve the regenerative ability has emerged as an alternative and promising approach for frailty (8).

Figure 1. Interrelationship among hallmarks of aging, clinical symptoms of frailty, and potential regenerative therapy. Aging people are constantly affected by oxidative stress and inflammatory responses throughout their later years. In an extreme condition of this interaction, frailty is developed and defined by 5 major criteria, including unintentional weight loss, exhaustion, slow gait speed, weak grip strength, and low physical activity. Frailty is strongly associated with the aging process, which includes 6 important hallmarks: genomic instability, deregulated proteostasis, nutrient sensing, metabolic malfunctions, cellular senescence, stem cell exhaustion, and compromised cell-cell communication. Emerging stem cell therapy provides a potential approach to tackle these problems by providing ex vivo cultured stem cells that are able to improve the frailty condition by multiple mechanisms. Full color version is available within the online issue.

To date, at least 4 clinical trials have been conducted to evaluate the safety and efficacy of mesenchymal stem/stromal cell (MSC) therapy in the treatment of frailty. Among them, 2 clinical trials (registered with the numbers NCT02982915 and NCT03169231) are ongoing multicenter, randomized, blinded, and placebo-controlled clinical studies using bone marrow-derived MSCs (BM-MSCs) (9). Another trial, Allogeneic Human Mesenchymal Stem Cells in Patients With Aging Frailty Via Intravenous Delivery (CRATUS) (NCT02065245), was recently completed by Joshua M. Hare and colleagues (10). The results confirm that all participating patients tolerated the allogeneic administration of bone marrow-derived MSCs (BM-MSCs) well. In terms of efficacy, the trial indicated that 100 million cell doses were more effective than 200 million cell doses (11). In the CRATUS study, BM-MSCs were isolated and expanded from bone marrow aspirate from male or female donors between the ages of 20 and 45 with a comprehensive screening history and physical status (10). Once collected, the BM-MSCs were expanded in 20% fetal bovine serum-supplemented media for 14 days and harvested at passage 1 for administration. In vivo evidence suggests that BM-MSCs can be affected by aging and are strongly associated with the mammalian life span and health conditions (12,13). Recently, our group reported the negative effects of type 2 diabetes mellitus duration on the quality and metabolic function of autologous BM-MSCs (14). Hence, the variation in efficacy observed in a recent study using BM-MSCs for the treatment of frailty could be due to (i) the heterogeneous sources of BM-MSCs, which were derived from a wide age range of BM-MSC donors, (ii) the in vitro culture of BM-MSCs in fetal bovine serum (unknown component, batch-to-batch variation, and animal-derived products), and (iii) the aging-related effects of BM-MSCs.

An alternative source of allo-MSCs is needed to fill the gap in knowledge and provides another option regarding the strengths and limitations of applying BM-MSCs as a source of stem cells for the treatment of frailty using regenerative medicine. Therefore, in this study, we propose a randomized controlled phase II/I trial involving the allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) for frailty.

Proposed Molecular Analysis of Stem Cell-Associated Efficacy in Frailty Treatment

To evaluate the interrelationship between the efficacy of the treatment and the nature and function of UC-MSCs, several molecular experiments have been planned and will be performed at baseline and at 1 month, 3 months, 6 months, and 9 months postadministration. (i) Analyses of cytokines, chemokines, and growth factors in patient plasma using cytokine/chemokine/growth factor 45-plex human ProcartaPlex panel-1 will provide information on the inflammation status and immune response of the patient to UC-MSC administration. (ii) The immunoregulatory properties of UC-MSCs on CD3+ T lymphocytes of patients will be evaluated. (iii) Measurements of cellular senescence by quantitative polymerase chain reaction (qPCR) will be conducted with the CD3+ T lymphocytes. (iv) The metabolic profiles of CD3+ cells will be evaluated using the Seahorse XF Cell Mito Stress Test Kit and Seahorse XF Cell Glycolysis Stress Test Kit (Agilent Technologies, Delaware, USA). (v) The expression of CD142 in different MSC products is associated with their procoagulant nature, which triggers instant blood-mediated inflammatory reactions via complex cascades of immunological reactions (15). A summary of the study procedure timeline and events is illustrated in Table 1 and Figure 2. The details of the study protocol are provided in Supplementary 1.
Table 1. Study Timeline and Clinical Procedures During the Trial

| Study Procedure                                         | Prescreening | Screening Phase* | Baseline | 1 Mo | 3 Mo | 6 Mo | 9 Mo |
|---------------------------------------------------------|--------------|------------------|----------|------|------|------|------|
| UC-MSC administration†                                   | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ ☑| ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Medication treatment‡                                     | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Informed consent                                         | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Inclusion and exclusion criteria                         | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Demographic information                                  | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Patient's medical reports                                | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Vital signs/physical examination                         | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Frailty evaluation†                                       | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Thrombotic analysis†                                      | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Hematology analysis‡                                      | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Infectious disease examination/test**                    | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Chest CT scan                                            | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Chest X-ray                                              | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Pulmonary function analysis††                            | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Adverse event evaluation                                 | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Monitoring of mortality/complications                    | ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |
| Blood sample for molecular and cellular analyses of frailty‡‡| ☑ ☑          | ☑                | ☑ ☑ ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ | ☑ ☑ |

Notes: APTT = activated partial thromboplastin time, BNP = brain natriuretic peptide, CT = computed tomography, FEV = forced expiratory volume, FEV1 = forced expiratory volume in 1 second, HBV = hepatitis B virus, HIV = human immunodeficiency virus, qPCR = quantitative polymerase chain reaction, RV = residual volume, SF-36 = short form 36 health survey, TLC = total lung capacity, UC-MSC = umbilical cord-derived mesenchymal stem/stromal cell, VC = vital capacity, WOMAC = the Western Ontario and McMaster University Arthritis Index.

†If the results of the screening phase for UC-MSC groups are within 30 days of UC-MSC administration, they will be automatically considered as the baseline level.

‡Applies only for the UC-MSC group at baseline and 3 months.

§Includes all medical evaluations and assessments of frailty.

**Infectious diseases include hepatitis, syphilis, HIV, HBV, and tuberculosis.

††Infectious diseases include hepatitis, syphilis, HIV, HBV, and tuberculosis.

Why Is It Important to Picture Aging Hallmarks in Such a Complexed Study Design?

The accumulation of senescent cells is one of the hallmarks of human aging and is tightly related to telomere shortening and DNA damage. The former has a profound impact on cell proliferation and senescence because the shortening of telomeres has been suggested as a useful biomarker for cellular senescence and aging (16). Although the interrelationship between telomere shortening and frailty has been proposed as a potential biomarker of frailty at the clinical level, no correlation between telomere length and frailty condition has been reported (17,18). In response to persistent DNA damage, cellular senescence occurs through activation of the INK4a/ARF (CDKN2a) locus, which leads to increased expression of p16INK4a, a cell cycle kinase inhibitor. Studies have revealed that p16INK4a is correlated with chronological age in both mice and humans, and the peripheral blood T-lymphocyte expression of p16INK4a has been established as an indicator of human aging (19). Moreover, recent study suggested that expression of p16INK4a is a biomarker of dysfunctional chondrocytes but is not essential for senescence-associated secretory phenotype (20). A meta-analysis of more than 300 genome-wide association studies demonstrated that the INK4a/ARF locus is generally linked to the highest number of age-associated pathologies, such as cardiovascular diseases, diabetes, glaucoma, and Alzheimer’s disease (21). In senescent cells, the structural change involved in the increased lysosomal content with the most widely used marker is the increased level of senescence-associated beta-galactosidase activity (22). In this study, the expression of p16INK4a and SA-b-gal will be examined in patient CD3+ cells before and after UC-MSC administration.

Summary

In this study, we emphasize the aims, significance, study design, and mechanistic investigation of the administration of allogeneic UC-MSCs for patients with frailty: a phase I/II clinical trial will be conducted to address the safety and potential efficacy of UC-MSC administration based on a set of clinical evaluations of frailty (including physiological and functional analyses and assessment...
of aging phenotypes). This study will also address the potential risk of thrombotic events after administration of the treatment in older participants. The data accumulated during this study will provide invaluable insight into the mechanism of action of MSCs in improving the aging conditions in patients with frailty and will provide an alternative treatment to improve the impact of frailty in older patients to a certain extent.

Supplementary Material

Supplementary data are available at The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences online.

Funding

This work was supported by the Vingroup Scientific and Clinical Research Grant (grant number: ISC.21.11).

Conflict of Interest

None declared.

Acknowledgments

The authors would like to thank all patients involved in the study for their trust, understanding, and willingness. We thank our collaborating clinicians at the Vinmec Health Care System for participating in this study.

References

1. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394(10206):1365–1375. doi:10.1016/S0140-6736(19)31786-6
2. Dung V, Thi Mai Lan N, Thu Trang V, et al. Quality of life of older adults in nursing homes in Vietnam. Health Psychol Open. 2020;7(2):2055102920954710. doi:10.1177/2055102920954710
3. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487–1492. doi:10.1111/j.1532-5415.2012.04054.x
4. Nguyen TV, Le D, Tran KD, Bui KX, Nguyen TN. Frailty in older patients with acute coronary syndrome in Vietnam. Clin Interv Aging. 2019;14:2213–2222. doi:10.2147/CIA.S234597
5. Fried LP, Tangen CM, Walston J, et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–M156. doi:10.1093/gerona/56.3.m146
6. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. doi:10.1016/j.cell.2013.05.039

7. Soysal P, Arik F, Smith L, Jackson SE, Isik AT. Inflammation, frailty and cardiovascular disease. Adv Exp Med Biol. 2020;1216:55–64. doi:10.1007/978-3-030-33330-0_7

8. Lim JE, Son Y. Endogenous stem cells in homeostasis and aging. Tissue Eng Regen Med. 2017;14(6):679–698. doi:10.1007/s13770-017-0097-3

9. Sun XL, Hao QK, Tang RJ, Xiao C, Ge ML, Dong BR. Frailty and rejuvenation with stem cells: therapeutic opportunities and clinical challenges. Rejuvenation Res. 2019;22(6):484–497. doi:10.1089/req.2017.2048

10. Golpanian S, DiFede DL, Pujol MV, et al. Rationale and design of the allogeneic human mesenchymal stem cells (hMSC) in patients with aging frailty via intravenous delivery (CRATUS) study: a phase II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty. Oncotarget. 2016;7(11):11399–11912. doi:10.18632/oncotarget.7727

11. Tompkins BA, DiFede DL, Khan A, et al. Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, double-blind, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci. 2017;72(11):1513–1522. doi:10.1093/gerona/glx137

12. Beane OS, Fonseca VC, Cooper LL, Koren G, Darling EM. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One. 2014;9(12):e115963. doi:10.1371/journal.pone.0115963

13. Zhou S, Greenberger JS, Epperly MW, et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell. 2008;7(3):335–343. doi:10.1111/j.1474-9726.2008.00377.x

14. Nguyen LT, Hoang DM, Nguyen KT, et al. Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells. Stem Cells Transl Med. 2021;10(9):1266–1278. doi:10.1002/sctm.20-0506

15. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360(9350):2039–2045. doi:10.1016/s0140-6736(02)12020-4

16. Ben-Porath I, Weinberg RA. When cells get stressed: an integrative view of cellular senescence. J Clin Invest. 2004;113(1):8–13. doi:10.1172/JCI20663

17. Mather KA, Jorm AF, Parslow RA, Christensen H. Is telomere length a biomarker of aging? A review. J Gerontol A Biol Sci Med Sci. 2011;66(2):202–213. doi:10.1093/gerona/glq180

18. Haapanen MJ, Perałá MM, Salonen MK, et al. Telomere length and frailty: the Helsinki Birth Cohort Study. J Am Med Dir Assoc. 2018;19(8):658–662. doi:10.1016/j.jamda.2018.05.011

19. Liu Y, Sanoff HK, Cho H, et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009;8(4):439–448. doi:10.1111/j.1474-9726.2009.00489.x

20. Diekman BO, Sessions GA, Collins JA, et al. Expression of p16INK 4a is a biomarker of chondrocyte aging but does not cause osteoarthritis. Aging Cell. 2018;17(4):e12771. doi:10.1111/acel.12771

21. Jeck WR, Siebold AP, Sharpless NE. Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell. 2012;11(5):727–731. doi:10.1111/j.1474-9726.2012.00871.x

22. Lee BY, Han JA, Im JS, et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell. 2006;5(2):187–195. doi:10.1111/j.1474-9726.2006.00199.x